Text Registration
Copyright Title
Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
Status
Published
on 7 Feb 2019
Year of Creation
2018
Copyright Claimant
Elsevier Inc
Registration Number
TX0008752767
on 7 Feb 2019Copyright Summary
The U.S. Copyright record (Registration Number: TX0008752767) dated 7 Feb 2019, pertains to an electronic file (eService) titled "Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy" created in 2018. The copyright holder is Elsevier Inc, known for their creative contributions in text registration. For any inquiries concerning this copyrighted material, kindly reach out to Elsevier Inc.
Application Details
Registration Number
TX0008752767
Registration Date
2/7/2019
Year of Creation
2018
Agency Marc Code
DLC-CO
Record Status
New
Physical Description
Electronic file (eService)
First Publication Nation
United States
ISBN
9780128164358
Preexisting Material
permissioned materials
Notes
Rights Note: permissions@elsevier.com
Local Copyright Note: C.O. correspondence
Material Matter Claimed Note: text
Statements
Application Title Statement: Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
Author Statement: Zhe Sheng Chen Citizenship: United States Authorship: text Dong Hua Yang Citizenship: United States Authorship: text
© 2023 reserved by Trademarkia
Show terms & conditions
Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal advice. Although LegalForce RAPC Worldwide P.C., dba Trademarkia P.C., is a law firm (the “Firm”), your use of this website does not establish an attorney-client relationship with the Firm. Such a relationship can only be established after the Firm decides that it is willing and able to accept the engagement after a conflict check and after a written retainer agreement is agreed upon between you and the Firm. Your use of this website is also subject to our Terms of Use and Privacy Policy. ** The entry level subscription is a bundled price which requires a minimum of two billing cycles, or 6 months.